A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

Abroad (travel likely)Recruiting

Conditions

Prostatic Neoplasms, Castration-Resistant

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Novartis, East Hanover, New Jersey, United States

Study leads

Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

mCRPC (Metastatic Castration-resistant Prostate Cancer) · Genital Diseases, Male · Urogenital Diseases, Male

Abroad (travel likely)RecruitingPHASE1, PHASE2

Detroit, United States · Clermont-Ferrand, France

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Prostate Adenocarcinoma · Metastatic Prostate Adenocarcinoma · Castration-resistant

Abroad (travel likely)RecruitingPHASE2

Baltimore, United States · Porto Alegre, Brazil

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

Neoplasms

Abroad (travel likely)RecruitingPHASE1

Lake Success, United States · Tugun, Australia

Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC

Prostatic Neoplasms, Castration-Resistant

Abroad (travel likely)RecruitingPHASE2

Albury, Australia · Camperdown, Australia